Literature DB >> 27636769

Implementing an antimicrobial stewardship program in out-patient dialysis units.

Cheston B Cunha1, Erika M C D'Agata.   

Abstract

PURPOSE OF REVIEW: Rates of multidrug-resistant organisms (MDRO), including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and multidrug-resistant gram-negative bacteria, continue to rise among the population of chronic hemodialysis. Antimicrobial exposure is the main risk factor for MDRO emergence and dissemination. Up to 30% of antimicrobial doses administered in out-patient dialysis units may not be indicated. Antimicrobial stewardship programs (ASP) improve antimicrobial prescribing patterns. The purpose of this review is to highlight the key elements and interventions of ASP. RECENT
FINDINGS: The Infectious Disease Society of America and the Society of Healthcare Epidemiology of America have provided evidence-based guidelines for the development and implementation of an ASP. Many of their recommendations can be adapted to the out-patient dialysis setting.
SUMMARY: Developing and implementing an ASP by following key elements and interventions in the out-patient dialysis setting can lead to reduced mortality, adverse events, costs, and improvement in antimicrobial susceptibility rates.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27636769      PMCID: PMC5747318          DOI: 10.1097/MNH.0000000000000281

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  18 in total

1.  Internet-based institutional antimicrobial stewardship program resources in leading US academic medical centers.

Authors:  Timothy P Gauthier; Evan Lantz; Alexander Heyliger; Sarah M Francis; Laura Smith
Journal:  Clin Infect Dis       Date:  2013-10-28       Impact factor: 9.079

2.  Guidance for the knowledge and skills required for antimicrobial stewardship leaders.

Authors:  Sara E Cosgrove; Elizabeth D Hermsen; Michael J Rybak; Thomas M File; Sarah K Parker; Tamar F Barlam
Journal:  Infect Control Hosp Epidemiol       Date:  2014-12       Impact factor: 3.254

3.  Vancomycin prescribing practices in hospitalized chronic hemodialysis patients.

Authors:  K Green; G Schulman; D W Haas; W Schaffner; E M D'Agata
Journal:  Am J Kidney Dis       Date:  2000-01       Impact factor: 8.860

4.  Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-05-15       Impact factor: 9.079

Review 5.  Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis.

Authors:  Emelie C Schuts; Marlies E J L Hulscher; Johan W Mouton; Cees M Verduin; James W T Cohen Stuart; Hans W P M Overdiek; Paul D van der Linden; Stephanie Natsch; Cees M P M Hertogh; Tom F W Wolfs; Jeroen A Schouten; Bart Jan Kullberg; Jan M Prins
Journal:  Lancet Infect Dis       Date:  2016-03-03       Impact factor: 25.071

6.  Vancomycin-resistant enterococci colonization among dialysis patients: a meta-analysis of prevalence, risk factors, and significance.

Authors:  Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Louis B Rice; Eleftherios Mylonakis
Journal:  Am J Kidney Dis       Date:  2014-07-17       Impact factor: 8.860

Review 7.  The Risks of Incident and Recurrent Clostridium difficile-Associated Diarrhea in Chronic Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Parkpoom Phatharacharukul; Charat Thongprayoon; Wisit Cheungpasitporn; Peter J Edmonds; Pailin Mahaparn; Jackrapong Bruminhent
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

8.  Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Authors:  Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

Review 9.  Optimizing Antibiotic Stewardship in Nursing Homes: A Narrative Review and Recommendations for Improvement.

Authors:  Christopher J Crnich; Robin Jump; Barbara Trautner; Philip D Sloane; Lona Mody
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

10.  Antimicrobial stewardship programs (ASPs): the devil is in the details.

Authors:  Cheston B Cunha; Christy A Varughese; Eleftherios Mylonakis
Journal:  Virulence       Date:  2013-02-04       Impact factor: 5.882

View more
  5 in total

1.  Clinical and Economic Benefits of Antimicrobial Stewardship Programs in Hemodialysis Facilities: A Decision Analytic Model.

Authors:  Erika M C D'Agata; Diana Tran; Josef Bautista; Douglas Shemin; Daniel Grima
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-23       Impact factor: 8.237

2.  Targeting Zero Infections in Dialysis: New Devices, Yes, but also Guidelines, Checklists, and a Culture of Safety.

Authors:  Alan S Kliger
Journal:  J Am Soc Nephrol       Date:  2018-03-05       Impact factor: 10.121

Review 3.  Antimicrobial resistance in nephrology.

Authors:  Tina Z Wang; Rosy Priya L Kodiyanplakkal; David P Calfee
Journal:  Nat Rev Nephrol       Date:  2019-08       Impact factor: 28.314

4.  Patterns of Antimicrobial Use in an Outpatient Hemodialysis Unit.

Authors:  Sylvia Sivarajahkumar; Miranda So; Andrew M Morris; Charmaine Lok; Chaim M Bell; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2022

5.  Study of the Antimicrobial Activity of the Chinese Dong Ethnic Minority Medicine, Madeng'ai.

Authors:  Zhenrong Tang; Yannan Zhao; Zaiqi Zhang; Huan Yue; Dan Wang; Shengchun Liu; Hua Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-01       Impact factor: 2.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.